An expert describes the efficacy of fenfluramine in decreasing seizure frequency associated with this rare syndrome.
Fenfluramine proved successful in decreasing seizure frequency in a Phase 3 study of Dravet syndrome, a rare pediatric condition known for its treatment resistance.
In this podcast, Dr. Wilner interviews Arnold Gammaitoni, PharmD, about this potentially game-changing new epilepsy drug.
If these results can be duplicated, it raises the possibility of a new, effective treatment for seizures in children with Dravet syndrome.
RELATED CONTENT: Dietary Therapy to Improve Epilepsy Outcomes: Case Vignettes
More podcasts here.